Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

Blay JY, Shen L, Kang YK, Rutkowski P, Qin S, Nosov D, Wan D, Trent J, Srimuninnimit V, Pápai Z, Le Cesne A, Novick S, Taningco L, Mo S, Green S, Reichardt P, Demetri GD.

Lancet Oncol. 2015 Apr 13. pii: S1470-2045(15)70105-1. doi: 10.1016/S1470-2045(15)70105-1. [Epub ahead of print]

PMID:
25882987
2.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouzid E, Santoro A, Franke FA, Cohen P, Le-Guennec S, Demetri GD.

Lancet Oncol. 2015 Apr 8. pii: S1470-2045(15)70102-6. doi: 10.1016/S1470-2045(15)70102-6. [Epub ahead of print]

PMID:
25864104
3.

[Rare hereditary tumours].

Nagy P, Lahm E, Pápai Z.

Magy Onkol. 2014 Jun;58(2):94-7. Epub 2013 Nov 10. Hungarian.

4.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L.

Lancet Oncol. 2014 May;15(6):580-91. doi: 10.1016/S1470-2045(14)70138-X. Epub 2014 Apr 14.

PMID:
24742739
5.

[Medical treatment of soft tissue sarcomas based on the histological subtype].

Pápai Z.

Magy Onkol. 2014 Mar;58(1):53-8. Epub 2014 Feb 1. Review. Hungarian.

6.

[Surgical treatment of retroperitoneal sarcomas].

Bursics A, Besznyák I, Mersich T, Pörneczi B, Dede K, Papp G, Ágoston P, Pápai Z.

Magy Onkol. 2014 Mar;58(1):47-51. Epub 2014 Feb 12. Review. Hungarian.

7.

[Resection and reconstruction in cases of musculosceletal soft tissue sarcomas].

Antal I, Kiss J, Perlaky T, Szalay K, Vancsó P, Oláh Z, Sápi Z, Pápai Z, Szendrői M.

Magy Onkol. 2014 Mar;58(1):32-6. Epub 2014 Mar 1. Review. Hungarian.

8.

Mass spectrometric identification of ancient proteins as potential molecular biomarkers for a 2000-year-old osteogenic sarcoma.

Bona A, Papai Z, Maasz G, Toth GA, Jambor E, Schmidt J, Toth C, Farkas C, Mark L.

PLoS One. 2014 Jan 27;9(1):e87215. doi: 10.1371/journal.pone.0087215. eCollection 2014.

9.

[Treatment of metastatic midgut neuroendocrine tumour associated with carcinoid syndrome].

Uhlyarik A, Lahm E, Vachaja J, Pápai Z.

Orv Hetil. 2014 Feb 1;155(5):194-8. doi: 10.1556/OH.2014.29818. Hungarian.

PMID:
24463166
10.

[Our experience with targeted therapy in glioblastoma multiforme].

Kiss E, Lahm E, Vachaja J, Nagy P, Bazsó P, Fekete Z, Takácsi-Nagy Z, Pápai Z.

Magy Onkol. 2013 Dec;57(4):264-8. doi: MagyOnkol.2013.57.4.264. Epub 2013 Nov 1. Hungarian.

11.

[Diagnosis and treatment options of neuroendocrine tumours].

Uhlyarik A, Pápai Z.

Orv Hetil. 2013 Sep 29;154(39):1549-55. doi: 10.1556/OH.2013.29716. Review. Hungarian.

PMID:
24058100
12.

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).

Changchien YC, Tátrai P, Papp G, Sápi J, Fónyad L, Szendrői M, Pápai Z, Sápi Z.

J Transl Med. 2012 Oct 30;10:216. doi: 10.1186/1479-5876-10-216.

13.

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R, Kirchner T, Heinemann V, Zielinski CC.

Oncology. 2012;83(5):241-7. Epub 2012 Aug 29.

PMID:
22948721
14.

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, Papai ZS, Karaseva N, Thongprasert S, Portulas ED, von Pawel J, Zhang K, Selaru P, Tye L, Chao RC, Govindan R.

J Clin Oncol. 2012 Jun 10;30(17):2070-8. doi: 10.1200/JCO.2011.39.2993. Epub 2012 May 7.

15.

Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma.

Balogh Z, Szemlaky Z, Szendroi M, Antal I, Pápai Z, Fónyad L, Papp G, Changchien YC, Sápi Z.

Diagn Pathol. 2011 Nov 3;6:107. doi: 10.1186/1746-1596-6-107.

16.

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM.

Lancet Oncol. 2011 Nov;12(12):1125-33. doi: 10.1016/S1470-2045(11)70259-5. Epub 2011 Oct 21.

PMID:
22019520
17.

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, Lindemann JP, Macpherson MP, Neven P.

Breast Cancer Res Treat. 2010 Sep;123(2):453-61. doi: 10.1007/s10549-010-1022-9. Epub 2010 Jul 15.

PMID:
20632084
18.

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.

World J Gastroenterol. 2010 Jul 7;16(25):3133-43.

19.

[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].

Küronya Z, Bodrogi I, Lövey J, Plótár V, Manninger S, Pápai Z.

Magy Onkol. 2009 Sep;53(3):263-6. doi: 10.1556/MOnkol.53.2009.3.5. Hungarian.

20.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY.

J Clin Oncol. 2009 Jul 1;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223. Epub 2009 May 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk